Sarepta Therapeutics (SRPT) Stock Price, Quote & News

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dy...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 274 4000

Website: www.sarepta.com

Address:

215 First Street, Suite 415, Cambridge, United States

obryanjfg Oct. 25 at 12:07 PM

$SRPT Goor try, but that Fierce Bio article (and the stated Elevdys rev) is from Q3 2024. Yes 2024. Try again!

0 · Reply

blueb22 Oct. 25 at 11:47 AM

$SRPT - and screen of main part on Elevidys in this article...

0 · Reply

blueb22 Oct. 25 at 11:45 AM

$SRPT - this is interesting and very good (didn't see this in normal Google search on Sarepta's news). This suggests US sales will be a huge upward surprise!!! https://www.fiercepharma.com/pharma/roche-sees-no-material-impact-eylea-biosim-surprise-elevidys-dmd-gene-therapy-beat?itm_source=parsely-api

0 · Reply

MoneyGroupLLC Oct. 25 at 10:35 AM

Enter: $SRPT Calls Strike Price: $23 Expiry Date: NOV 14 2025 Buy in Price: $1.84 - $3.10 Sell Price: $3.00 Profit : +63% (Turn every $1 into $1.63) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

tedevan Oct. 25 at 8:04 AM

$SRPT anyway to gauge if they big $15 puts were being sold ?

0 · Reply

Lost_My_Shadow Oct. 25 at 2:46 AM

$SRPT Family is some of the worst culprits of abandoning and milking. Lend $10 k to any one of your family members and count the days till that relationship blows up. Borrow 10 k from anyone of them and same will happen

0 · Reply

Bezhadimmu Oct. 25 at 2:42 AM

$SRPT go jays! Fuck the dodgers! Their team a bunch of over paid zero chemistry bums! Jays are organically built!

0 · Reply

MoneyGroupLLC Oct. 25 at 2:23 AM

Enter: $SRPT NOV 14 2025 $24 CALLS Buy in Price: $1.60 - $2.85 Take Profit: $3.68 Stop Bleeding: $1.41 ROI Potential: 130% https://moneygroup.us/

0 · Reply

conloco Oct. 25 at 1:51 AM

$SRPT Can’t wait for earnings for Doug to preach what’s been going behind the scenes. All signs point to a great quarter. The weird timing of events and possible buyout talks have surely caused a long overdue PR. Maybe it’s the best course and all of it will make sense in the coming weeks. Nonetheless, not trading this. Just sitting on my position and excited for what’s to come

0 · Reply

Bezhadimmu Oct. 25 at 1:24 AM

$SRPT we have no proof of buyout but can you please provide proof there will not be a buyout. Thank you. Waiting.

3 · Reply

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

BLSH DASH FLY IREN NEM OPEN QS

Oct 10, 2025, 11:49 AM EDT - 14 days ago

Sarepta Therapeutics: A Discounted Valuation Meets Breakthrough Pipeline

Oct 8, 2025, 11:19 AM EDT - 16 days ago

What's Going On Sarepta Stock On Wednesday?

Oct 3, 2025, 8:30 AM EDT - 21 days ago

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

Sep 30, 2025, 6:00 PM EDT - 24 days ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 5, 2025, 9:00 AM EDT - 7 weeks ago

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

Aug 28, 2025, 6:20 AM EDT - 2 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN IONS MRNA

Aug 25, 2025, 3:11 AM EDT - 2 months ago

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

Aug 23, 2025, 7:08 AM EDT - 2 months ago

SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline (NASDAQ:SRPT)

Aug 22, 2025, 12:12 PM EDT - 2 months ago

Sarepta Therapeutics: A Strong Opportunity Amidst The Panic

Aug 22, 2025, 9:50 AM EDT - 2 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Aug 21, 2025, 7:00 AM EDT - 2 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027

Aug 20, 2025, 3:30 PM EDT - 2 months ago

SRPT Update: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline

Aug 18, 2025, 12:01 PM EDT - 2 months ago

Sarepta Therapeutics (SRPT) August 25, 2025 Lead Plaintiff Deadline Approaching, SRPT Investors with Substantial Losses Encouraged to Contact Hagens Berman

Aug 14, 2025, 12:14 PM EDT - 2 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Aug 13, 2025, 4:12 PM EDT - 2 months ago

Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment

Aug 13, 2025, 8:33 AM EDT - 2 months ago

SAREPTA STOCK: Lose Money on Your Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investment? Contact BFA Law before the August 25 Legal Deadline

Aug 11, 2025, 8:18 AM EDT - 2 months ago

SRPT COURT NOTICE: Sarepta Therapeutics Investors may have been Affected by Fraud -- Contact BFA Law before August 25 if You Suffered Losses (NASDAQ:SRPT)

Aug 11, 2025, 5:26 AM EDT - 2 months ago

These Stocks Are Moving the Most Today: Coinbase, MicroStrategy, Sarepta, Nvidia, AMD, and More

AMD COIN MSTR NVDA

Aug 6, 2025, 4:05 PM EDT - 2 months ago

Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments

Jul 31, 2025, 8:48 AM EDT - 3 months ago

Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results

Jul 31, 2025, 8:45 AM EDT - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Therapeutics, Inc. Lawsuit - SRPT

Jul 30, 2025, 11:07 AM EDT - 3 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR CABA NGNE NTLA QURE RCKT

Jul 30, 2025, 8:36 AM EDT - 3 months ago

SRPT INVESTORS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investors may have been Affected by Fraud – Contact BFA Law by August 25 about Potentially Recovering Losses

Jul 29, 2025, 5:48 PM EDT - 3 months ago

Opinion | On Sarepta, a Welcome FDA Reversal

Jul 29, 2025, 2:47 PM EDT - 3 months ago

Sarepta finally gets some good news: A patient death wasn't its DMD drug's fault.

Jul 29, 2025, 2:06 PM EDT - 3 months ago

SRPT Rallies on FDA Green Light: A New Bottom for the Stock?

Jul 29, 2025, 1:27 PM EDT - 3 months ago

FDA Lifts Safety Hold On Sarepta's Muscular Dystrophy Gene Therapy—Wall Street Cheers

Jul 29, 2025, 10:40 AM EDT - 3 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Jul 29, 2025, 9:00 AM EDT - 3 months ago

Sarepta: SRPT Stock To $40?

Jul 29, 2025, 8:38 AM EDT - 3 months ago

Sarepta shares soar 36% after FDA clears partial resumption of Elevidys shipments

Jul 29, 2025, 7:21 AM EDT - 3 months ago

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

Jul 29, 2025, 7:01 AM EDT - 3 months ago

Sarepta resumes shipping of gene therapy Elevidys to patients who can walk

Jul 29, 2025, 5:01 AM EDT - 3 months ago

Sarepta Stock Just Soared 45%. Here's Why.

Jul 28, 2025, 5:09 PM EDT - 3 months ago

FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy

Jul 28, 2025, 4:59 PM EDT - 3 months ago

US FDA recommends removal of hold on Sarepta's Elevidys in some patients

Jul 28, 2025, 8:36 AM EDT - 3 months ago

SRPT LAWSUIT: Sarepta Therapeutics, Inc. Sued for Fraud after Patient Deaths – Contact BFA Law by August 25 Court Deadline (NASDAQ:SRPT)

Jul 28, 2025, 7:30 AM EDT - 3 months ago

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

ARWR

Jul 28, 2025, 5:46 AM EDT - 3 months ago

Sarepta Stock Drops After Downgrade and FDA Probe. The Crisis Explained.

Jul 28, 2025, 4:17 AM EDT - 3 months ago

Sarepta Therapeutics: Beaten Down, But Not Out

Jul 27, 2025, 1:37 PM EDT - 3 months ago

Opinion | The Sarepta Mugging and Drug Innovation

Jul 25, 2025, 7:51 PM EDT - 3 months ago

Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS

Jul 25, 2025, 5:54 PM EDT - 3 months ago

US FDA investigates third death after treatment with Sarepta's gene therapy Elevidys

obryanjfg Oct. 25 at 12:07 PM

$SRPT Goor try, but that Fierce Bio article (and the stated Elevdys rev) is from Q3 2024. Yes 2024. Try again!

0 · Reply

blueb22 Oct. 25 at 11:47 AM

$SRPT - and screen of main part on Elevidys in this article...

0 · Reply

blueb22 Oct. 25 at 11:45 AM

0 · Reply

MoneyGroupLLC Oct. 25 at 10:35 AM

0 · Reply

tedevan Oct. 25 at 8:04 AM

$SRPT anyway to gauge if they big $15 puts were being sold ?

0 · Reply

Lost_My_Shadow Oct. 25 at 2:46 AM

0 · Reply

Bezhadimmu Oct. 25 at 2:42 AM

$SRPT go jays! Fuck the dodgers! Their team a bunch of over paid zero chemistry bums! Jays are organically built!

0 · Reply

MoneyGroupLLC Oct. 25 at 2:23 AM

Enter: $SRPT NOV 14 2025 $24 CALLS Buy in Price: $1.60 - $2.85 Take Profit: $3.68 Stop Bleeding: $1.41 ROI Potential: 130% https://moneygroup.us/

0 · Reply

conloco Oct. 25 at 1:51 AM

0 · Reply

Bezhadimmu Oct. 25 at 1:24 AM

$SRPT we have no proof of buyout but can you please provide proof there will not be a buyout. Thank you. Waiting.

3 · Reply

Retter7 Oct. 25 at 1:22 AM

$SRPT Elevidys is crushing sales even after the pause. Demand’s real, and the stock looks way undervalued right now. Could be a sleeper pick. 💎📈

0 · Reply

The_Scientist Oct. 25 at 1:22 AM

$SRPT Book of the Genome — Chapter II: The Long Hold Madness 2:1 Hear ye, ye disciples of the biotech flame, Analysts squawk, but we play the insane game! 2:2 Their “price targets” crawl like worms in clay, FUDsters screech, “It’s down today!” But the genome hums, the prophets say— SRPT will melt their decay! 2:3 And lo! Saint Sarepta, gene-made flame, Burns the shorters, erases shame, Analyst liars, know your blame— Our biotech god shall rename the game! Amen

0 · Reply

Retter7 Oct. 25 at 12:48 AM

$SRPT Analysts have issued 12-month price targets, with an average of $24.35 and estimates reaching as high as $80. The outlook suggests that meaningful developments may be unfolding behind the scenes, and I intend to remain invested to capture the potential upside. As I’ve stated before, my position remains firm I won’t be selling until this stock reaches triple digits.

0 · Reply

Thaigrlsrk Oct. 25 at 12:34 AM

$SRPT Do not forget Ian Guided they could continue to fund ALL 4 ARWR drugs development with just revenues from PMO's and Elevidys Ambulant kids only.

0 · Reply

biomaster22 Oct. 25 at 12:18 AM

$SRPT market up huge srpt up 1.00 total bs Nobody believes in Doug Buyout that’s a pipe dream !

1 · Reply

Vision2025 Oct. 24 at 11:48 PM

$SRPT 60+

0 · Reply

Find_the_Cure Oct. 24 at 11:42 PM

$SRPT let’s do this!!!

0 · Reply

AnydayAnytime Oct. 24 at 11:15 PM

$SRPT

2 · Reply

Thaigrlsrk Oct. 24 at 10:37 PM

$SRPT Nut job wants Sarepta sold to Roche for 10, Sarepta will not sell less then 20 EOS. Why would they? because the SP is down where it shouldn't be ? If Sarepta was 10 now they might sell for 20 but i doubt it. This is a company and a management that just made the deal of a lifetime with ARWR, and has the revenue (even without the non ambs)to build a powerhouse Pharma and that is what DI and Ian are about.

1 · Reply

Fred_Sigma_Invest Oct. 24 at 10:30 PM

$SRPT Good Luck, Bulls!

0 · Reply

LearnedPatience Oct. 24 at 9:46 PM

$SRPT pay us! $150+

0 · Reply

Initiator1 Oct. 24 at 9:30 PM

$SRPT Several actions taken by the company in last 6 months are clear buyout signals. However, I think there’s a deadlock in negotiations - perhaps the differential between the buyout offer and asking price is huge. For context, just about a years back, the company won’t sell for less than $300/share (c. $30 billion valuation). Here’s what I think is happening: Roche or some other big pharma want the company for $7-8 bn. $SRPT management doesn’t want to sell for less than $15 bn. Anyway, we can all wish the buyout is announced soon and at $100+ / share.

2 · Reply

Market Cap	2.14B
Revenue (ttm)	1.90B
Net Income (ttm)	235.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	12.37%
Debt to Equity Ratio	0.84

Volume	3,730,400
Avg Vol	6,674,762
Day's Range	N/A - N/A
Shares Out	97.71M
Stochastic %K	64%
Beta	0.51
Analysts	Sell
Price Target	$24.57